[18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer
出版年份 2020 全文链接
标题
[18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer
作者
关键词
-
出版物
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-02-11
DOI
10.1007/s00259-019-04532-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Paclitaxel and Pazopanib in Ovarian Cancer—Reply
- (2018) Debra L. Richardson et al. JAMA Oncology
- Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer
- (2018) Debra L. Richardson et al. JAMA Oncology
- Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Radoslav Chekerov et al. LANCET ONCOLOGY
- Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies
- (2017) Rahul Aggarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of vascular normalization in benefit from metronomic chemotherapy
- (2017) Fotios Mpekris et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients
- (2016) R. B. Verheijen et al. CLINICAL CANCER RESEARCH
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial
- (2016) Yeo-Eun Kim et al. Cancer Research and Treatment
- Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI
- (2015) J Guo et al. BRITISH JOURNAL OF CANCER
- Plasma radiometabolite correction in dynamic PET studies: Insights on the available modeling approaches
- (2015) Matteo Tonietto et al. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
- Multicenter Reproducibility of 18F-Fluciclatide PET Imaging in Subjects with Solid Tumors
- (2015) R. Sharma et al. JOURNAL OF NUCLEAR MEDICINE
- Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial
- (2015) Sandro Pignata et al. LANCET ONCOLOGY
- Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy
- (2014) Sanne de Haas et al. ANGIOGENESIS
- Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma
- (2014) A B Suttle et al. BRITISH JOURNAL OF CANCER
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
- (2014) Andreas du Bois et al. JOURNAL OF CLINICAL ONCOLOGY
- Does Imaging v 3 Integrin Expression with PET Detect Changes in Angiogenesis During Bevacizumab Therapy?
- (2014) S. N. Rylova et al. JOURNAL OF NUCLEAR MEDICINE
- Preliminary clinical assessment of the relationship between tumor alphavbeta3 integrin and perfusion in patients studied with [18F]fluciclatide kinetics and [15O]H2O PET
- (2014) Laura M Kenny et al. EJNMMI Research
- Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy
- (2013) A Necchi et al. BRITISH JOURNAL OF CANCER
- Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report
- (2013) Julia L. Glade Bender et al. JOURNAL OF CLINICAL ONCOLOGY
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
- (2012) Diether Lambrechts et al. LANCET ONCOLOGY
- Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies
- (2012) James P. B. O'Connor et al. Nature Reviews Clinical Oncology
- Comparison Study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET Imaging of U87MG Tumors in Mice
- (2011) Lixin Lang et al. BIOCONJUGATE CHEMISTRY
- HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer
- (2011) E. A. Stronach et al. CANCER RESEARCH
- Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics
- (2011) T. Yau et al. CLINICAL CANCER RESEARCH
- Quantification of receptor-ligand binding with [18F]fluciclatide in metastatic breast cancer patients
- (2011) Giampaolo Tomasi et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer
- (2011) Jonathan A. Ledermann et al. JOURNAL OF CLINICAL ONCOLOGY
- Monitoring Tumor Response to Antiangiogenic Sunitinib Therapy with 18F-Fluciclatide, an 18F-Labeled V 3-Integrin and V 5-Integrin Imaging Agent
- (2011) M. R. Battle et al. JOURNAL OF NUCLEAR MEDICINE
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy
- (2010) V Goede et al. BRITISH JOURNAL OF CANCER
- Plasma Cytokine and Angiogenic Factor Profiling Identifies Markers Associated with Tumor Shrinkage in Early-Stage Non-Small Cell Lung Cancer Patients Treated with Pazopanib
- (2010) P. G. Nikolinakos et al. CANCER RESEARCH
- Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer
- (2010) Ernest S. Han et al. GYNECOLOGIC ONCOLOGY
- Phase I Trial of Pazopanib in Patients with Advanced Cancer
- (2009) H. I. Hurwitz et al. CLINICAL CANCER RESEARCH
- Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study
- (2009) Jennifer M. Rubatt et al. GYNECOLOGIC ONCOLOGY
- Radiosynthesis and Biodistribution of Cyclic RGD Peptides Conjugated with Novel [18F]Fluorinated Aldehyde-Containing Prosthetic Groups
- (2008) Matthias Glaser et al. BIOCONJUGATE CHEMISTRY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacodynamic Biomarker Study of Sorafenib in Metastatic Renal Carcinoma
- (2008) Olwen M. Hahn et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of the Positron-Emitting Arg-Gly-Asp (RGD) Peptide Radioligand 18F-AH111585 in Breast Cancer Patients
- (2008) L. M. Kenny et al. JOURNAL OF NUCLEAR MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started